|
Re: ESC 2019 Symposium: Epigenetics: A new pathway to tackle residual risk?
|
3
|
Resverlogix Corp.
|
Jul 06, 2019 01:53PM
|
|
Re: Equity financing
|
3
|
Zenith Epigenetics
|
Jun 25, 2018 03:27PM
|
|
Re: Epigenetics: an exciting new approach in prostate cancer
|
4
|
Zenith Epigenetics
|
Apr 09, 2019 03:27PM
|
|
Re: Epigenetics market to reach $16.3 Billion in 6 years (article)
|
3
|
Resverlogix Corp.
|
Jan 18, 2016 05:57PM
|
|
Re: Epigenetics market to reach $16.3 Billion in 6 years (article)
|
2
|
Resverlogix Corp.
|
Jan 20, 2016 05:34PM
|
|
Re: Epigenetics market size
|
3
|
Zenith Epigenetics
|
Jan 25, 2024 11:48AM
|
|
Re: Enthusiasm? NOT!
|
6
|
Zenith Epigenetics
|
Oct 30, 2021 12:56PM
|
|
Re: Enthusiasm? NOT!
|
3
|
Zenith Epigenetics
|
Oct 30, 2021 06:00PM
|
|
Re: Entertainment During Wait
|
2
|
Resverlogix Corp.
|
Aug 25, 2017 03:24PM
|
|
Re: Endocyte Valuation
|
2
|
Zenith Epigenetics
|
Oct 19, 2018 01:00PM
|
|
Re: empagliflozin - a drug competitive to rvx-208???
|
3
|
Resverlogix Corp.
|
Nov 09, 2015 11:42AM
|
|
Re: EDITRe: i would love to hear,..
|
|
Resverlogix Corp.
|
Dec 06, 2019 10:55AM
|
|
Re: early report imo
|
4
|
Resverlogix Corp.
|
Jul 03, 2022 12:09PM
|
|
Re: early report imo
|
5
|
Resverlogix Corp.
|
Jul 03, 2022 06:50PM
|
|
Re: DSMB 7th review??
|
4
|
Resverlogix Corp.
|
Jul 20, 2018 04:40PM
|
|
Re: Drugmakers, scientists begin the hunt for long COVID treatments
|
4
|
Resverlogix Corp.
|
Mar 26, 2022 07:24AM
|
|
Re: Drug Discovery Targeting BRD4
|
4
|
Resverlogix Corp.
|
Oct 04, 2017 05:09PM
|
|
Re: Dropping on the opening on the "pinks"
|
3
|
Resverlogix Corp.
|
Jul 29, 2015 12:39PM
|
|
Re: Drop in price
|
4
|
Resverlogix Corp.
|
Jul 09, 2021 11:03AM
|
|
Re: Dr. Wong retires - Dr. Kulikowski in as CSO
|
4
|
Resverlogix Corp.
|
Aug 15, 2022 07:08PM
|
